Overview
Gonadorelin is a synthetic form of endogenous GnRH, the hypothalamic decapeptide (pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) that controls the entire reproductive hormone axis. First synthesized by Nobel laureate Andrew Schally in 1971, its discovery revolutionized reproductive endocrinology.
When administered in pulsatile fashion, gonadorelin stimulates LH and FSH release, promoting gonadal function and fertility. Continuous administration causes receptor desensitization and HPG suppression—a property exploited in prostate cancer and endometriosis treatment.
FDA-approved as a diagnostic agent (Factrel®), gonadorelin is increasingly used off-label for testosterone restoration in secondary hypogonadism as an alternative to TRT that preserves fertility.
This guide examines gonadorelin's pharmacology, clinical applications, and its expanding role in hormone optimization.
Quick facts
- Mechanism
- Endogenous GnRH analog stimulating pituitary LH/FSH release
- Primary use
- HPG Axis Stimulation & Fertility Preservation
- Evidence
- strong
- FDA
- Approved
- Route
- Intravenous, subcutaneous, or intranasal
- Typical results
- LH and FSH rise within 15–30 minutes of IV/SC injection
Chemical information
Gonadorelin (C₅₅H₇₅N₁₇O₁₃) is a hormonal compound with a molecular weight of 1182.29 g/mol. Its structural characteristics underpin its biological activity in hormonal signaling and endocrine function.
How Gonadorelin works
Gonadorelin binds GnRH receptors on anterior pituitary gonadotropes, activating Gq/11-coupled signaling including phospholipase C, IP3-mediated calcium mobilization, and PKC activation. This triggers exocytosis of LH and FSH granules followed by de novo gonadotropin synthesis.
The critical distinction is between pulsatile (every 60–120 min, stimulatory) and continuous (desensitizing) GnRH exposure. Pulsatile delivery maintains receptor expression and supports gonadotropin synthesis, mimicking physiology.
GnRH pulse frequency differentially regulates LH vs FSH: high-frequency pulses (q60min) favor LH via LHβ transcription, while low-frequency pulses (q2–4h) favor FSH via FSHβ transcription.
In secondary hypogonadism, pulsatile gonadorelin restores LH-driven testosterone production and FSH-driven spermatogenesis, unlike exogenous testosterone which suppresses both.
- GnRHR activation: Triggers Gq/11-PLC-IP3-Ca2+ cascade in pituitary gonadotropes
- LH/FSH release: Induces rapid gonadotropin exocytosis within minutes
- Pulsatile stimulation: Maintains receptor sensitivity and axis function
- Frequency coding: High-frequency favors LH; low-frequency favors FSH
- Fertility preservation: Maintains spermatogenesis unlike exogenous testosterone
- Axis restoration: Re-establishes endogenous HPG axis in secondary hypogonadism
Pharmacokinetics
| Parameter | Value | Significance |
|---|---|---|
| Bioavailability | Rapid and complete IV/SC absorption | Short half-life necessitates pulsatile delivery for therapeutic use |
| Onset of Action | LH rise within 5–15 minutes; peak at 20–45 minutes | Time to measurable clinical/biological response |
| Half-life | 2–10 minutes | Determines dosing frequency |
| Duration of Effect | LH elevation persists 3–5 hours | Functional activity beyond plasma clearance |
| Metabolism | Rapid enzymatic degradation by serum endopeptidases | Primary elimination pathway |
Dosing & administration
Gonadorelin dosing varies by indication and individual factors. Refer to the official prescribing information for approved indications.
Any use should be conducted under qualified medical supervision with appropriate monitoring of safety markers.
Side effects & safety
Safety data for Gonadorelin is established for approved indications via clinical trials. Long-term effects in humans remain incompletely characterized.
Common
- • Injection site reactions
- • Headache
- • Flushing
- • Nausea
- • Abdominal discomfort
- • Light-headedness
Serious / potential risks
- • Anaphylaxis (very rare, <0.1%)
- • Multi-dose anaphylaxis (antibody formation)
- • Ovarian hyperstimulation in women
- • Pituitary apoplexy (extremely rare)
- • Urticaria
Drug interactions
| Medication | Interaction | Recommendation |
|---|---|---|
| GnRH agonists (leuprolide) | Unpredictable HPG axis effects from pharmacological conflict | Avoid combination or use with extreme caution under medical supervision |
| Exogenous testosterone | Testosterone suppresses pituitary GnRH receptors, blunting response | Avoid combination or use with extreme caution under medical supervision |
| Oral contraceptives | Exogenous hormones suppress gonadotrope sensitivity | Monitor closely; dose adjustment may be required |
| Dopamine agonists | May modestly reduce GnRH-stimulated LH release | Generally safe; monitor if concerns arise |
Storage & handling
Lyophilized Powder
- • Store at room temperature (20–25°C)
- • Protect from light
- • Stable 2+ years sealed
- • Reconstitute with supplied diluent
Reconstituted Solution
- • Refrigerate at 2–8°C
- • Use within 24 hours for diagnostics
- • Replace pump solution every 48 hours
- • Do not freeze
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research suppliers | Varies widely | Quality and purity vary significantly between sources |
| Compounding pharmacies | Prescription required | Higher quality assurance and purity testing |
The bottom line
Gonadorelin is a hormonal compound with research interest in fertility, gnrh, hormonal regulation, pct. While preclinical evidence is encouraging, it has received FDA approval for specific indications. Any use should be under qualified medical supervision.
Best for
- • Researchers studying hormonal signaling and endocrine function
- • Individuals interested in fertility under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
Frequently asked questions
References
- [1] Schally AV, Arimura A, Baba Y, et al.. Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun (1971). PMID: 4943955
- [2] Belchetz PE, Plant TM, Nakai Y, et al.. Hypophysial responses to continuous and intermittent delivery of GnRH. Science (1978). doi: 10.1126/science.96497 PMID: 96497
- [3] Dwyer AA, Quinton R.. Gonadotropins for spermatogenesis induction in hypogonadotropic men. Best Pract Res Clin Endocrinol Metab (2015). doi: 10.1016/j.beem.2015.04.009 PMID: 26051301
- [4] Sykiotis GP, Hoang XH, Avbelj M, et al.. Congenital idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab (2010). doi: 10.1210/jc.2009-2582 PMID: 20357178